Q-omics provides the consensus-scored MFN2 profile across patient tissues and cancer cell-line models. MFN2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MFN2 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, MFN2 protein abundance shows 34,019 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, THCA, and GBM as cancer lineages where MFN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MFN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MFN2 survival associations across molecular data types. MFN2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MFN2 RNA expression–survival associations across cancer types. High MFN2 expression shows unfavorable associations in KICH, ACC and LGG, but favorable associations in KIRC, SCLC and KIRP. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MFN2 RNA expression.
This table summarizes MFN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MFN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MFN2 shows lower tumor expression in THCA, KIRC, COAD, BLCA and LUAD and higher tumor expression in HNSC. The THCA box plot shows higher MFN2 RNA expression in normal versus tumor tissue (log2 FC = −0.498, t-test p < 0.001).
This table shows molecular features associated with MFN2 in patient tissues and cancer cell lines. In patient samples, MFN2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MFN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
